Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
View original at finance.yahoo.comProtagonist Therapeutics Announces U.S…
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
Nearly one-quarter of all people with plaque psoriasis have cases that are considered moderate to severe
60% confidenceNearly one-quarter of all people with plaque psoriasis have cases that are considered moderate to severe
60% confidencePsoriasis affects more than eight million Americans
60% confidenceRates of adverse reactions for ICOTYDE treated patients were within 1.1% of placebo through Week 16 and no new safety signals were identified through Week 52
60% confidenceTransition to systemic therapy is recommended if two cycles of topical medications applied for four weeks fail to bring meaningful improvement
60% confidenceICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill
60% confidenceMore than 125 million people worldwide live with plaque psoriasis
60% confidenceThis is the beginning of a multi-year product-driven growth cycle for Protagonist Therapeutics
60% confidenceThe FDA approval of ICOTYDE demonstrates the strength of Protagonist's peptide technology platform to generate innovative therapies
60% confidenceICOTYDE offers a novel plaque psoriasis treatment that combines the established efficacy and safety of IL-23 pathway blockade with the convenience of a once-daily oral pill
60% confidenceTransition to systemic therapy is recommended if two cycles of topical medications applied for four weeks fail to bring meaningful improvement
60% confidenceWith the pending FDA decision for rusfertide this year, and the financial resources for accelerating pipeline investment, this is the beginning of a multi-year product-driven growth cycle for Protagonist Therapeutics
60% confidenceApproximately 70% of patients achieved clear or almost clear skin (IGA 0/1) and 55% of patients achieved a PASI90 response at Week 16 in head-to-head studies
60% confidenceRates of adverse reactions for ICOTYDE treated patients were within 1.1% of placebo through Week 16 and no new safety signals were identified through Week 52
60% confidenceThe FDA approval of ICOTYDE demonstrates the strength of Protagonist's peptide technology platform to generate innovative therapies
60% confidenceICOTYDE offers a novel plaque psoriasis treatment that combines the established efficacy and safety of IL-23 pathway blockade with the convenience of a once-daily oral pill
60% confidenceApproximately 70% of patients achieved clear or almost clear skin (IGA 0/1) and 55% of patients achieved PASI90 response at Week 16 in head-to-head studies
60% confidencePsoriasis affects more than eight million Americans
60% confidenceICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance
60% confidenceMore than 125 million people worldwide live with plaque psoriasis
60% confidence